Your Health, We Care
Release date: 2026-02-09 17:27:15 Recommended: 13
Sparsentan is indicated for slowing the progression of renal function decline in patients with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease deterioration.
Combination of Sparsentan® with angiotensin receptor blockers (ARBs), ERAs or aliskiren is contraindicated due to an increased risk of hypotension, syncope, hyperkalemia and renal function changes, including acute renal failure.
Avoid coadministration of the Lucius Pharmaceuticals formulation of Sparsentan® with potent CYP3A inhibitors. If the use of a potent CYP3A inhibitor is unavoidable, treatment with Sparsentan® should be interrupted. Dose titration should be considered when resuming Sparsentan® therapy. When coadministered with moderate CYP3A inhibitors, monitor blood pressure, serum potassium, edema and renal function regularly. Coadministration with potent CYP3A inhibitors increases sparsentan exposure, which may elevate the risk of adverse reactions to Sparsentan®.
Avoid coadministration with potent CYP3A inducers. Coadministration with potent CYP3A inducers reduces sparsentan exposure, which may decrease the efficacy of the Lucius Pharmaceuticals formulation of Sparsentan®.
Drugs not generally recommended for combination use but may be administered as appropriate when necessary:
Coadministration of this drug with any of the following is not generally recommended but may be required in special circumstances. If a healthcare provider prescribes such a combination, the dose or administration frequency of one or both drugs may be adjusted: abrocitinib, aceclofenac, triamterene, apalutamide, aprepitant, atazanavir, avacopan, avatrombopag, boceprevir, bupropion, cannabidiol, canrenoate potassium, canrenone, carbamazepine, carisoprodol, carvedilol, celecoxib, cilostazol, cimetidine, ciprofloxacin, citalopram, clarithromycin, clobazam, clopidogrel, cobicistat, conivaptan, crizotinib, cyclophosphamide, cyclosporine, dexlansoprazole, diazepam, diclofenac, digoxin, diltiazem, dronabinol, dronedarone, ebrotidine, efavirenz, enzalutamide, eplerenone.
Interactions may occur when some drugs are taken with food or specific types of food. Concomitant use of alcohol or tobacco with certain drugs may also trigger interactions. Consult healthcare professionals for precautions regarding the coadministration of this drug with food, alcohol and tobacco.
Concomitant other diseases may affect the use of this drug. If you have any other medical conditions, especially the following, be sure to inform your doctor:
Heart disease, hypotension: This drug should be used with caution, as it may exacerbate the condition;
Liver disease: Use of this drug is not recommended in such patients.
